香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，2023年8月14日 InnoCare Pharma Limited 諾誠健華醫藥有限公司 (於開曼群島註冊成立的有限公司) (股份代號：9969) 董事會召開日期 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2023年8月29日（星期二）舉行董事會會議，藉以（其中包括）考慮並批准本公司及 其附屬公司截至2023年6月30日止六個月中期業績及其發佈。 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士； 非執行董事施一公博士、謝榕剛先生及金明先生；以及獨立非執行董事胡蘭女士 及陳凱先博士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 為確定股東出席股東特別大會並於會上投票的資格，本公司將由二零二三年八月 二十八日（星期一）至二零二三年八月三十一日（星期四）（首尾兩日包括在內）暫 停辦理股份過戶登記手續，期間將不會辦理任何股份的過戶登記。 為符合資格出席股東特別大會並於會上投票，所有股份過戶文件連同有關股票最 遲須於二零二三年八月二十五日（星期五）下午四時三十分前送達本公司的證券過 戶登記處香港中央證券登記有限公司的辦事處（地址為香港灣仔皇后大道東183號 合和中心17樓1712-1716號舖）以作登記。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9969） 暫停辦理股份過戶登記手續 諾誠健華醫藥有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公 司將於二零二三年八月三十一日（星期四）舉行特別大會（「股東特別大會」），以供 本公司股東（「股東」 ...

Financial Performance - The company's revenue for Q1 2023 was RMB 189,387,628.40, representing a year-on-year increase of 58.99%[4] - Pharmaceutical sales revenue reached RMB 151,370,102.78, an increase of 43.46% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of RMB 12,406,466.71, with a year-on-year decrease of 89.51%[4][8] - Total revenue for Q1 2023 was RMB 189.39 million, a 59% increase from RMB 119.12 million in Q1 2022[19] - Net profit for Q1 2023 was a loss of RMB 14.23 million, significantly improved from a loss of RMB 120.62 million in Q1 2022[20] - Comprehensive income for Q1 2023 was a loss of RMB 100.50 million, compared to a loss of RMB 141.11 million in Q1 2022[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB -153,933,775.03[4] - Operating cash inflow totaled $187.54 million, up from $139.50 million year-over-year[23] - Cash outflow from operating activities reached $341.47 million, compared to $277.49 million in the previous year[23] - Net cash flow from operating activities was -$153.93 million, worsening from -$137.99 million year-over-year[23] - Cash inflow from investment activities was $41.31 million, down from $55.79 million in the previous year[23] - Cash outflow from investment activities amounted to $43.22 million, significantly lower than $1.67 billion in the previous year[23] - Net cash flow from investment activities was -$1.92 million, compared to -$1.61 billion year-over-year[23] - Cash flow from financing activities resulted in a net outflow of -$9.03 million, compared to -$8.51 million in the previous year[25] - The ending balance of cash and cash equivalents was $3.99 billion, down from $1.47 billion year-over-year[25] Research and Development - R&D expenses totaled RMB 140,950,687.03, accounting for 74.42% of revenue, a decrease of 34.20 percentage points year-on-year[5][8] - R&D expenses increased to RMB 140.95 million, up from RMB 129.40 million, reflecting a growth of about 8.5%[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 10,215,914,005.30, a decrease of 1.09% from the end of the previous year[5] - The total assets of the company decreased to approximately ¥10.22 billion from ¥10.33 billion, a decline of about 1.1%[18] - Total liabilities decreased slightly to approximately ¥2.65 billion from ¥2.68 billion, a reduction of about 1.4%[17] - The company reported a total equity of approximately ¥7.57 billion, down from ¥7.64 billion, indicating a decrease of about 1.1%[18] - The company’s total current liabilities amounted to approximately ¥2.04 billion, a slight decrease from ¥2.07 billion, reflecting a reduction of about 1.6%[17] Shareholder Information - The company had a total of 23,135 common shareholders at the end of the reporting period[9] - HKSCC NOMINEES LIMITED held 41.13% of the shares, making it the largest shareholder[10] Other Income and Expenses - The company reported a government subsidy of RMB 11,137,224.44 included in non-recurring gains and losses[6] - Other income decreased to RMB 11.14 million from RMB 21.40 million, a decline of approximately 48.2%[19] - Investment loss improved to RMB -0.71 million from RMB -3.16 million, indicating a positive trend[20] - The company reported a foreign exchange loss of RMB -6.46 million, compared to a loss of RMB -5.55 million in the previous year[20] Employee Compensation - The company reported a significant increase in cash paid to employees, totaling $146.72 million, compared to $117.42 million in the previous year[23]

Financial Performance - The company's revenue for Q1 2023 was RMB 189,387,628.40, representing a year-on-year increase of 58.99%[5] - Pharmaceutical sales revenue reached RMB 151,370,102.78, an increase of 43.46% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of RMB 12,406,466.71, with no applicable year-on-year comparison[5] - Total operating revenue for Q1 2023 was RMB 189,387,628.40, an increase of 59% compared to RMB 119,120,479.12 in Q1 2022[21] - The net loss attributable to shareholders of the parent company was RMB -12,406,466.71, compared to a loss of RMB -118,242,516.18 in the same period last year, indicating a significant improvement[22] - The comprehensive loss for the period was RMB -100,502,461.88, compared to RMB -141,110,240.31 in the previous year, showing an improvement of approximately 29%[23] - Basic earnings per share for Q1 2023 was -0.01, compared to -0.08 in Q1 2022, indicating a reduction in loss per share[23] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB -153,933,775.03[5] - In Q1 2023, the total cash inflow from operating activities was CNY 187,540,094.29, an increase from CNY 139,499,711.45 in Q1 2022, representing a growth of approximately 34.4%[25] - The net cash flow from operating activities was negative at CNY -153,933,775.03, compared to CNY -137,986,042.27 in the same period last year, indicating a decline in operational cash generation[25] - The total cash and cash equivalents at the end of Q1 2023 were CNY 3,993,788,388.71, down from CNY 1,466,666,021.40 at the end of Q1 2022, reflecting a decrease of approximately 72.8%[26] - The company reported a total cash outflow of CNY 186,195,342.28 in Q1 2023, compared to a much larger outflow of CNY 1,770,818,284.18 in Q1 2022, indicating a significant improvement in cash management[26] Research and Development - R&D expenses totaled RMB 140,950,687.03, accounting for 74.42% of revenue, a decrease of 34.20 percentage points year-on-year[6] - Research and development expenses increased to RMB 140,950,687.03, up from RMB 129,396,070.62, reflecting a growth of about 8.5%[21] Assets and Liabilities - The total assets at the end of the reporting period were RMB 10,215,914,005.30, a decrease of 1.09% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 10,215,914,005.30, a decrease from CNY 10,328,783,979.11 at the end of 2022[17] - The total liabilities decreased to RMB 2,647,592,989.19 from RMB 2,684,457,313.64, a reduction of approximately 1.4%[22] - The total equity attributable to shareholders of the parent company was RMB 7,522,918,266.25, down from RMB 7,597,101,016.92, a decrease of about 1%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,135[10] - The top ten shareholders hold a combined 41.13% of shares, with HKSCC NOMINEES LIMITED holding the largest share at 725,666,837 shares[12] - Vivo Capital Fund VIII, L.P. and its concerted actions hold 129,668,118 shares, representing 7.35%[14] Foreign Exchange and Financial Expenses - The company experienced a negative impact of CNY -21,312,065.11 from foreign exchange fluctuations on cash and cash equivalents[26] - The company reported a financial expense of RMB -101,409,201.80, which is a significant increase from RMB -37,723,802.06 in the previous year[21] Inventory and Receivables - Accounts receivable increased to CNY 131,389,817.39 from CNY 127,824,970.72[17] - Inventory rose significantly to CNY 98,915,173.76 compared to CNY 65,321,825.92[18] Investment Activities - The cash inflow from investment activities totaled CNY 41,307,536.32, down from CNY 55,785,270.27 in Q1 2022, a decrease of approximately 26.0%[25] - The net cash flow from investment activities was negative at CNY -1,915,385.25, compared to CNY -1,613,305,227.02 in the previous year, indicating a significant reduction in investment losses[25] - Cash outflows for the acquisition of fixed assets and intangible assets were CNY 43,222,921.57, significantly lower than CNY 204,862,322.68 in Q1 2022, showing a decrease of about 78.9%[25] Collaboration and Rights - The company regained global rights for the drug Oubatinib after terminating a collaboration agreement with BeiGene, which included a one-time payment of USD 125 million[16]

Financial Performance - The company reported a net loss of 894 million yuan for 2022, with a cash-adjusted loss of 474 million yuan after excluding non-cash items[3]. - The company does not plan to distribute profits for the 2022 fiscal year, pending approval at the annual shareholders' meeting[5]. - The company reported a revenue of RMB 1.2 billion for the fiscal year, representing a year-over-year increase of 25%[13]. - The company's operating revenue for 2022 was ¥625,404,169.95, a decrease of 40.04% compared to ¥1,043,032,783.04 in 2021[21]. - The net profit attributable to shareholders was -¥886,593,114.73, worsening from -¥64,546,012.27 in the previous year[21]. - The net cash flow from operating activities was -¥490,583,554.63, a decline of 393.66% compared to ¥167,058,314.75 in 2021[21]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a 25% growth compared to the previous year[17]. - The company reported a revenue of 625 million yuan for 2022, a decrease of 418 million yuan compared to 1.043 billion yuan in the previous year, while product sales revenue increased by 163.6%[153]. Research and Development - Research and development expenses increased by 28.05% year-on-year to 649 million yuan, excluding one-time licensing fees[3]. - The company is investing RMB 500 million in R&D for new technologies and drug development[13]. - The company is investing 150 million RMB in new technology development to improve drug delivery systems[17]. - Research and development expenses accounted for 103.73% of operating revenue, an increase of 33.48 percentage points from 70.25% in 2021[22]. - The company has 13 products in clinical trials, with a focus on oncology and autoimmune diseases, and has received conditional approval for Tafasitamab from the National Medical Products Administration as of April 26, 2023[29]. - The company has established a comprehensive R&D platform, including compound optimization and drug solubility enhancement technologies, to accelerate drug discovery[29]. - The company has established four core technology platforms, including compound optimization and drug solubility enhancement, to accelerate drug discovery and development[136]. - The company has established a research and development team of over 410 personnel and a commercialization team of over 260 personnel, but risks exist regarding the potential loss of key personnel due to industry competition[200]. Product Pipeline and Innovation - The company has established a rich product pipeline in hematological malignancies, autoimmune diseases, and solid tumors, with its core product, Orelabrutinib, already commercialized[3]. - Tafasitamab has been approved in Hong Kong and is being used as a clinically needed imported drug at the Boao Super Hospital[3]. - The company emphasizes a commitment to innovation driven by science and patient needs, focusing on drug development in oncology and autoimmune diseases[3]. - The company has highlighted various risk factors in its operations, which are detailed in the management discussion and analysis section of the report[4]. - The company aims to establish a leadership position in the hematological malignancies field, leveraging Obatoclax and a robust pipeline of investigational drugs[35]. - The company is developing multiple products targeting B-cell and T-cell signaling pathways for autoimmune diseases, aiming to meet unmet clinical needs globally[31]. - The company is actively pursuing market expansion and new product development across various therapeutic areas, including oncology and autoimmune diseases[50]. Market Expansion and Strategic Partnerships - Market expansion plans include entering two new international markets by Q3 2024[13]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[13]. - A strategic partnership with a leading biotech firm was announced to accelerate drug development timelines[13]. - The company aims to increase its market share by 10% in the next two years through targeted marketing strategies[13]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[17]. Clinical Trials and Regulatory Approvals - The company is conducting multiple I/II phase clinical trials for its self-developed products ICP-192 and ICP-723 in China, the US, and Australia, targeting various solid tumors[150]. - The company is conducting over 30 clinical trials across more than 100 clinical centers globally as of April 26, 2023[146]. - The company is actively communicating with the FDA regarding the clinical trial suspension and has submitted a revised clinical trial protocol[65]. - The FDA has requested additional information and data from the company to resolve the clinical trial suspension issues as soon as possible[65]. - The company is conducting a phase III clinical trial for Obatoclax as a first-line treatment for CLL/SLL, with patient recruitment over halfway completed[36]. Risks and Challenges - There is a risk of continued losses in the future due to the long and costly process of drug development and commercialization[3]. - The company acknowledges the risk of not achieving profitability in the near term due to ongoing R&D costs and the need for substantial investment in clinical trials and market preparation[152]. - The company faces risks related to delays in clinical trial progress, which may increase development costs and delay product launches compared to competitors[156]. - The company faces risks related to the inability to timely respond to changes in pharmaceutical industry regulations or policies, which could adversely affect its business[170]. - The company may experience supply shortages or interruptions if it cannot establish stable relationships with suppliers for raw materials and equipment[171]. Financial Position and Investments - The company has a strong cash flow situation despite ongoing investments in clinical trials and new drug preparations[3]. - The company's total assets increased by 39.30% to ¥10,328,783,979.11 at the end of 2022, up from ¥7,414,969,891.00 in 2021[21]. - The net assets attributable to shareholders rose by 35.55% to ¥7,597,101,016.92, compared to ¥5,604,559,524.19 at the end of 2021[21]. - The company raised funds through its initial public offering on the Sci-Tech Innovation Board, which contributed to the increase in total and net assets[22]. - The company successfully raised 2.919 billion CNY through the issuance of 264 million shares on the STAR Market, enhancing its capital structure[49].

Financial Performance - InnoCare Pharma reported a significant increase in revenue, reaching approximately $150 million for the fiscal year 2022, representing a year-over-year growth of 25%[22]. - The company reported a total revenue of RMB 625.4 million for the year ended December 31, 2022, a decrease of 40.1% from RMB 1,043.0 million in 2021[53]. - The company reported a net loss of $30 million for the fiscal year 2022, primarily due to increased R&D expenses, which rose by 40% compared to the previous year[22]. - The net loss for the year increased to RMB 893.7 million in 2022 from RMB 66.7 million in 2021[56]. - The adjusted loss for the year was RMB 473.691 million, a substantial decline from an adjusted profit of RMB 2.630 million in the previous year[58]. - The company's total expenses rose to RMB 1,550.5 million in 2022, up from RMB 1,161.1 million in 2021, primarily due to increased clinical trial and employee costs[55]. - Other income and gains decreased to RMB 198.2 million in 2022 from RMB 217.9 million in 2021, mainly due to the absence of foreign exchange gains in 2022[54]. - The company reported a foreign exchange loss of RMB 290.6 million in 2022, a significant shift from a gain of RMB 57.1 million in 2021[160]. Research and Development - The company is actively developing new technologies, with three drug candidates currently in late-stage clinical trials, including ICP-105 and ICP-192, expected to enter the market by 2024[22]. - The company has a strong pipeline with 13 valuable drug candidates, including 2 commercialized products and over 30 ongoing global trials across various clinical stages[33]. - The company is conducting a Phase II clinical trial for Orelabrutinib in primary immune thrombocytopenia (ITP), achieving a 36.4% overall response rate for the primary endpoint as of February 6, 2023[35]. - The company is focused on expanding its market presence and enhancing its research capabilities to meet global and regional market demands[34]. - The company has established a robust operational framework to support its ongoing clinical trials and product development initiatives[33]. - The company aims to address significant unmet clinical needs in autoimmune therapies through innovative B-cell and T-cell pathway developments[34]. - The company is committed to precision medicine and aims to provide competitive treatment solutions for solid tumors through its research and development efforts[66]. Market Expansion and Strategy - Looking ahead, InnoCare Pharma projects a revenue growth of 30% for the next fiscal year, driven by the anticipated launch of new products and expansion into international markets[22]. - InnoCare Pharma plans to expand its market presence in Europe and North America, targeting a 15% market share in these regions within the next three years[22]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $500 million allocated for this purpose[62]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share within the next two years[62]. - The company has initiated partnerships with leading research institutions to accelerate the development of its drug candidates, aiming to reduce time-to-market by 20%[22]. Product Development and Clinical Trials - The mid-term analysis of the global Phase II trial for the BTK inhibitor, Orelabrutinib, showed a significant reduction in disease activity in relapsing-remitting multiple sclerosis patients, with a 92.1% reduction in Gd+T1 lesion accumulation in the 80 mg QD group[35]. - The Phase IIa trial for Orelabrutinib in systemic lupus erythematosus (SLE) showed positive results, confirming safety and dose-dependent efficacy with a significant SLE responder index (SRI)-4 response rate[35]. - ICP-332, a novel TYK2 inhibitor, completed Phase I clinical trials in March 2022 and initiated Phase II trials for atopic dermatitis in China in the second half of 2022[36]. - ICP-488, a selective TYK2 allosteric inhibitor, began Phase I trials in August 2022, with single and multiple ascending dose parts completed[37]. - The company is conducting a registrational Phase III trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, with over half of the patients recruited[39]. - The company is conducting multiple I/II clinical trials for Gunagratinib in China, the US, and Australia, including a registration trial for cholangiocarcinoma initiated at the end of 2022[136]. Financial Position and Investments - InnoCare Pharma's cash reserves stand at $250 million, providing a solid financial foundation to support ongoing research and development efforts[22]. - The company has a cash reserve of RMB 9.1 billion at the end of 2022, providing financial security and flexibility for future operations[62]. - The company raised approximately RMB 2.919 billion through its listing on the STAR Market starting September 21, 2022[146]. - The company's cash and bank balances reached RMB 8,697.9 million as of December 31, 2022, compared to RMB 5,928.7 million as of December 31, 2021[165]. - The company has maintained effective operations during the COVID-19 pandemic, with no significant disruptions to clinical trials or supply chains reported[147]. Corporate Governance and Sustainability - The company is committed to enhancing its corporate governance practices, aligning with the latest industry standards to ensure transparency and accountability[22]. - The management team emphasized a commitment to sustainability, with plans to invest $50 million in green technologies over the next three years[62].

| A 股代码：688428 | A 股简称：诺诚健华 | 公告编号：2023-007 | | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华-B | | 诺诚健华医药有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 4 月 27 日(星期四)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2023 年 4 月 27 日上午 11:00-12:00 （二） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心网络互动 三、 参加人员 投资者可于 2023 年 4 月 2 ...

Financial Performance - Total revenue for the year ended December 31, 2022, was RMB 625.4 million, a decrease of 40% from RMB 1,043.0 million in the previous year[2]. - Net loss for the year increased significantly to RMB 893.7 million in 2022 from RMB 66.7 million in 2021[6]. - Adjusted net loss, excluding non-cash items, was RMB 473.7 million for the year ended December 31, 2022, compared to a profit of RMB 2.6 million in the previous year[8]. - Gross profit decreased from RMB 977.4 million in 2021 (gross margin: 93.7%) to RMB 482.0 million in 2022 (gross margin: 77.1%) due to reduced business cooperation revenue[97]. - The total loss for the year was RMB 893.73 million, compared to a loss of RMB 66.68 million in the previous year, reflecting a substantial increase in losses[153]. - The company reported a pre-tax loss of RMB 893,727,000 for the year 2022, compared to a pre-tax loss of RMB 20,121,000 in 2021[181]. - The company reported a net asset value of RMB 7,644.33 million as of December 31, 2022, compared to RMB 5,658.92 million in 2021, indicating growth in equity[154]. Drug Sales and Revenue Growth - Sales of the drug Orelabrutinib increased by 163.6% to RMB 565.9 million for the year ended December 31, 2022, compared to RMB 214.7 million in the previous year[3]. - Oubatinib generated product revenue of RMB 565.9 million for the year ending December 31, 2022, representing a 164% increase from RMB 214.7 million in the same period of 2021, driven by the successful implementation of the new national medical insurance drug list[12]. - The core product, Obinutuzumab, achieved a revenue growth rate of 163.6% year-over-year in fiscal year 2022[16]. - Drug sales net revenue increased by RMB 352.1 million or 164.0% to RMB 566.8 million in 2022[96]. - Revenue from mainland China for the year 2022 was RMB 568,035,000, a significant increase from RMB 216,066,000 in 2021, while overseas revenue decreased to RMB 57,369,000 from RMB 826,967,000[166]. Clinical Trials and Pipeline Development - The company is advancing a strong pipeline of 13 valuable drugs, including 2 commercialized products, and over 30 ongoing global clinical trials[9]. - The company is focused on developing therapies targeting B-cell and T-cell pathways for autoimmune diseases, addressing significant unmet clinical needs[10]. - The global Phase II trial of the BTK inhibitor, Oubatinib, for relapsing-remitting multiple sclerosis achieved its primary endpoint, showing a significant reduction in disease activity with a 92.1% decrease in Gd+T1 lesion accumulation in the 80 mg QD group compared to placebo (p=0.0006)[11]. - The company is conducting a Phase III trial for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Oubatinib monotherapy with rituximab plus bendamustine, having recruited over half of the patients[12]. - The company is actively recruiting patients for a registrational Phase II trial in the U.S. for relapsed/refractory mantle cell lymphoma (MCL), with an NDA submission expected next year[13]. - The company is advancing a Phase II trial of ICP-332, a novel TYK2 inhibitor, for atopic dermatitis (AD) after completing Phase I trials in March 2022[12]. - The company is conducting a registrational Phase III trial for MCD subtype DLBCL, comparing Oubatinib combined with R-CHOP therapy against R-CHOP alone, with a complete response rate of 75% in first-line patients[13]. Research and Development - The company doubled the number of research scientists in its drug discovery team and expanded its clinical team in 2022, enhancing global R&D capabilities[18]. - The company is committed to precision medicine, aiming to benefit more patients through tailored treatment approaches[83]. - The company is focused on expanding its market presence and enhancing its product pipeline through research and development initiatives[198]. - The company is exploring the potential of broad FGFR inhibitors and TRK inhibitors in its research and development efforts[196]. - The company is actively pursuing new drug applications (NDA) for its clinical candidates to ensure timely market entry[196]. Financial Position and Assets - As of December 31, 2022, the company had total assets of RMB 9,299.71 million, an increase from RMB 6,417.11 million in 2021[154]. - Current assets net value as of December 31, 2022, was RMB 7,224.3 million, driven by cash and bank balances of RMB 8,697.9 million[111]. - Cash and bank balances increased to RMB 9,011.2 million as of December 31, 2022, from RMB 6,550.5 million as of December 31, 2021, mainly due to net proceeds from the issuance of RMB shares and funds received from financing activities[130]. - The company's total debt rose from RMB 1,306.0 million as of December 31, 2021, to RMB 2,000.0 million as of December 31, 2022, primarily due to increases in long-term payables and other current liabilities[121]. - Trade receivables increased significantly from RMB 45.3 million to RMB 127.8 million, reflecting the growth in sales of pharmaceuticals and R&D services[111][113]. Corporate Governance and Compliance - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and internal controls[145]. - The company has adopted the corporate governance code and believes its current structure does not impair the balance of power between the board and management[142]. - The company is enhancing its corporate governance practices in line with the listing rules and regulations[194]. - The audit committee has reviewed the audited consolidated financial statements for the year ended December 31, 2022, in conjunction with the independent auditor[145]. Market and Strategic Initiatives - The company aims to expand its commercial product portfolio and maintain strong revenue growth for flagship products included in the national medical insurance catalog[16]. - The company plans to enhance its pipeline through internal development and strategic licensing opportunities[23]. - The company is committed to advancing innovative treatments and technologies in the pharmaceutical sector[197]. - The company is focused on addressing unmet medical needs in oncology and autoimmune diseases through innovative therapies[196]. - The company is actively pursuing collaborations and partnerships to enhance its research capabilities and market reach[197].

Financial Performance - In Q3 2022, the sales revenue of Orelabrutinib (Yinokai®) reached RMB 183 million, a 64% increase compared to Q2 2022, and a 129% increase year-on-year for the first nine months of 2022, totaling RMB 400 million[4]. - The total operating revenue for Q3 2022 was RMB 196 million, a decrease of 77.76% year-on-year, primarily due to a strategic cooperation agreement with BeiGene in Q3 2021 that generated RMB 776 million in licensing revenue[5]. - The net loss attributable to shareholders for Q3 2022 was RMB 393 million, representing a 232.11% increase compared to the same period last year[7]. - Revenue for the current reporting period decreased by 77.76% compared to the same period last year, primarily due to a high one-time technology licensing income recognized in the previous year[11]. - Net profit attributable to shareholders decreased by 232.11% in the current reporting period, influenced by the high technology licensing income recognized in the previous year[11]. - Total operating revenue for the first three quarters of 2022 was CNY 441.61 million, a significant decrease from CNY 981.43 million in the same period of 2021[24]. - Net profit for the first three quarters of 2022 was a loss of CNY 842.65 million, compared to a profit of CNY 87.31 million in the same period of 2021[25]. - Basic and diluted earnings per share for the third quarter of 2022 were both CNY -0.59, compared to CNY 0.06 in the same quarter of 2021[26]. Research and Development - Research and development expenses for the first nine months of 2022 amounted to RMB 475 million, reflecting a 30% increase after excluding the previous year's upfront payment to Incyte Corporation[5]. - The R&D expenses accounted for 100.71% of operating revenue in Q3 2022, reflecting a 55.14 percentage point increase compared to the same period last year[7]. - R&D investment decreased by 50.85% in the current reporting period, mainly due to last year's payment related to Incyte[13]. - The proportion of R&D investment to operating revenue increased by 55.14 percentage points in the current reporting period, reflecting the company's increased focus on R&D[13]. - The company has 13 products in various stages of clinical trials, with several others in preclinical stages, indicating a robust pipeline for future growth[4]. Assets and Liabilities - The company's total assets as of September 30, 2022, were RMB 10.43 billion, a 40.68% increase year-on-year[7]. - Total assets increased by 40.68% year-to-date, primarily due to the increase in funds raised from the A-share listing[13]. - The company's equity attributable to shareholders reached CNY 7,736,172,992.15, up from CNY 5,604,559,524.19, representing an increase of about 37.9%[22]. - Total liabilities increased to CNY 2,649,251,273.58 from CNY 1,756,050,524.82, which is an increase of approximately 50.7%[22]. Cash Flow and Liquidity - As of September 30, 2022, the company held cash and cash equivalents exceeding RMB 9.2 billion, with net cash exceeding RMB 7.7 billion, ensuring sufficient liquidity for ongoing projects[5]. - The net cash flow from operating activities decreased by 241.19% year-to-date, attributed to high one-time technology licensing payments received in the previous year and increased personnel costs due to a rise in R&D and production staff[11]. - Cash flow from operating activities showed a net outflow of CNY 395.32 million in 2022, contrasting with a net inflow of CNY 279.98 million in 2021[27]. - The net increase in cash and cash equivalents was 1,176,888,160.90 CNY, down from 2,133,772,073.22 CNY, indicating a decrease in overall liquidity growth[28]. - Cash inflow from investments totaled 2,789,411,528.74 CNY, an increase from 2,526,674,475.99 CNY, suggesting enhanced investment attraction[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 118,973[15]. - The company issued a total of 1,764,321,452 shares, with 85% listed in Hong Kong and 15% on the Shanghai Stock Exchange[14]. - The top ten shareholders hold a combined 88.10% of the company's shares, with HKSCC NOMINEES LIMITED holding 41.07%[16]. - The number of shares held by the top ten shareholders includes significant stakes from HKSCC NOMINEES LIMITED with 724,573,837 shares and HHLR Fund, L.P. with 208,671,222 shares[18]. Strategic Focus - The company continues to focus on expanding its market presence and developing innovative therapies for unmet clinical needs in oncology and autoimmune diseases[4]. - The company plans to focus on market expansion and new product development to improve future performance[24]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[19]. Financial Management - The company incurred financial expenses of CNY 311.95 million, compared to a financial income of CNY 98.51 million in the previous year[24]. - Total cash inflow from financing activities reached 3,129,667,311.83 CNY, up from 2,526,674,475.99 CNY, reflecting a strong increase in financing efforts[28]. - Net cash flow from financing activities was 3,106,021,468.26 CNY, compared to 2,505,380,367.38 CNY in the previous period, showing improved financial management[28]. Other Financial Metrics - The company reported a significant increase in sales expenses, which rose to CNY 290.26 million from CNY 187.45 million year-over-year[24]. - Other comprehensive income after tax for the first three quarters of 2022 was CNY 563.17 million, compared to a loss of CNY 2.96 million in the same period of 2021[25]. - Investment activities generated cash inflow of CNY 144.46 million in 2022, a sharp decline from CNY 2.12 billion in 2021[27]. - The company has adopted new accounting standards starting from 2022, which may affect financial reporting and analysis[29].

Financial Performance - InnoCare Pharma's sales revenue for the third quarter of 2022 reached RMB 195.65 million, a decrease of 77.76% compared to the same period last year[6] - The company's total revenue for the first nine months of 2022 was RMB 441.61 million, a 115% increase after excluding the impact of a strategic partnership with BeiGene in Q3 2021[5] - The company's operating revenue for the current reporting period decreased by 77.76% compared to the same period last year, primarily due to a high one-time technology licensing income recognized in the previous year[11] - Total operating revenue for the first three quarters of 2022 was CNY 441,612,184.36, a decrease from CNY 981,429,657.21 in the same period of 2021[23] - Net profit for the third quarter of 2022 was a loss of CNY 842,652,515.00, contrasting with a profit of CNY 87,305,248.88 in the same quarter of 2021[24] - The net loss attributable to shareholders for Q3 2022 was RMB 392.81 million, a 232.11% increase compared to the same period last year[7] - The net profit attributable to shareholders for the current reporting period decreased by 232.11% compared to the same period last year, influenced by the high technology licensing income from the previous year[11] Research and Development - Sales of the drug Orelabrutinib (宜诺凯®) amounted to RMB 183 million in Q3 2022, representing a 64% increase from Q2 2022 and a 129% increase year-on-year for the first nine months of 2022[4] - Research and development expenses for the first nine months of 2022 totaled RMB 475 million, reflecting a 30% increase compared to the previous year[5] - The company's R&D expenditure accounted for 100.71% of its revenue in Q3 2022, an increase of 55.14 percentage points year-on-year[7] - The company's R&D investment as a percentage of operating revenue increased by 55.14 percentage points for the current reporting period, reflecting a significant increase in R&D spending[12] - The company has 13 products in various stages of clinical trials, indicating a robust pipeline for future growth[4] Assets and Liabilities - The total assets of InnoCare Pharma as of Q3 2022 were RMB 10.43 billion, a 40.68% increase compared to the previous year[7] - The total assets increased by 40.68% compared to the end of the previous period, mainly due to the increase in funds raised from the A-share listing[12] - The total liabilities as of the end of the third quarter of 2022 were CNY 2,649,251,273.58, compared to CNY 1,756,050,524.82 at the end of the previous year[22] - The total equity attributable to shareholders of the parent company was CNY 7,736,172,992.15, an increase from CNY 5,604,559,524.19 in the previous year[22] Cash Flow and Liquidity - As of September 30, 2022, the company held cash and cash equivalents exceeding RMB 9.2 billion, ensuring sufficient liquidity for ongoing projects[5] - Operating cash flow for the first nine months was negative at -395,317,143.03, compared to a positive cash flow of 279,981,380.12 in the same period last year[27] - Total cash inflow from operating activities was 542,296,157.15, while cash outflow was 937,613,300.18, resulting in a net cash flow from operating activities of -395,317,143.03[27] - Cash inflow from investment activities totaled 144,458,064.46, with cash outflow amounting to 1,862,513,669.37, leading to a net cash flow from investment activities of -1,718,055,604.91[28] - Financing activities generated a cash inflow of 3,129,667,311.83, while cash outflow was 23,645,843.57, resulting in a net cash flow from financing activities of 3,106,021,468.26[28] - The company reported a net increase in cash and cash equivalents of 1,176,888,160.90, bringing the ending balance to 4,414,372,466.48[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 118,973[14] - The top ten shareholders held a significant portion of shares, with HKSCC NOMINEES LIMITED owning 724,573,837 shares, representing 41.07%[16] - The company reported a total of 1,589,900 shares lent out through margin trading as of the reporting period[17] - The company has engaged in strategic placements, with Guangzhou High-tech Zone Technology Holdings Group acquiring 8,975,521 shares[17] Other Financial Metrics - The weighted average return on equity was -7.53% for Q3 2022, a decrease of 12.81 percentage points from the previous year[7] - The company reported a foreign exchange loss of CNY -13,278,019.54 in the third quarter of 2022, compared to a loss of CNY -38,875,062.81 in the previous year[24] - The total comprehensive income for the third quarter of 2022 was CNY -279,487,002.07, compared to CNY 84,340,648.28 in the same quarter of 2021[25] - Basic earnings per share for the third quarter of 2022 were CNY -0.59, compared to CNY 0.06 in the same quarter of 2021[25] - The company reported a decrease in basic earnings per share of ¥233.33 for the current reporting period, influenced by the high technology licensing income from the previous year and foreign exchange losses[11]